Alok Krishen

3.4k total citations · 1 hit paper
32 papers, 2.0k citations indexed

About

Alok Krishen is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Alok Krishen has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 12 papers in Physiology and 10 papers in Pharmacology. Recurrent topics in Alok Krishen's work include Treatment of Major Depression (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers) and Smoking Behavior and Cessation (8 papers). Alok Krishen is often cited by papers focused on Treatment of Major Depression (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers) and Smoking Behavior and Cessation (8 papers). Alok Krishen collaborates with scholars based in United States, United Kingdom and Netherlands. Alok Krishen's co-authors include Peter H. Westfall, David Lawrence, Robert West, A. Eden Evins, Thomas McRae, Robert M. Anthenelli, Cristina Russ, Neal L. Benowitz, John A. Ascher and Jack G. Modell and has published in prestigious journals such as The Lancet, Neurology and Biological Psychiatry.

In The Last Decade

Alok Krishen

31 papers receiving 1.9k citations

Hit Papers

Neuropsychiatric safety and efficacy of varenicline, bupr... 2016 2026 2019 2022 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    2016 632 citations Robert M. Anthenelli, Neal L. Benowitz et al. The Lancet profile →

Peers

Alok Krishen
Daniel E. Falk United States
Thomas McRae United States
Harris A. Eyre Australia
Margaret Rukstalis United States
Nassima Ait‐Daoud United States
Kaifeng Lu United States
Udi E. Ghitza United States
Loukia M. Spineli Germany
Ajeet Singh Australia
Eftihia Linardatos United States
Daniel E. Falk United States
Alok Krishen
Citations per year, relative to Alok Krishen Alok Krishen (= 1×) peers Daniel E. Falk

Countries citing papers authored by Alok Krishen

Since Specialization
Citations

This map shows the geographic impact of Alok Krishen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alok Krishen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alok Krishen more than expected).

Fields of papers citing papers by Alok Krishen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alok Krishen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alok Krishen. The network helps show where Alok Krishen may publish in the future.

Co-authorship network of co-authors of Alok Krishen

This figure shows the co-authorship network connecting the top 25 collaborators of Alok Krishen. A scholar is included among the top collaborators of Alok Krishen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alok Krishen. Alok Krishen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gathe, Joseph, Moti Ramgopal, Charlotte-Paige Rolle, et al.. (2025). Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 99(2). 185–194. 1 indexed citations
2.
3.
Heffner, Jaimee L., A. Eden Evins, Cristina Russ, et al.. (2019). Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. Journal of Affective Disorders. 256. 267–277. 16 indexed citations
4.
Anthenelli, Robert M., Neal L. Benowitz, Robert West, et al.. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 387(10037). 2507–2520. 632 indexed citations breakdown →
5.
Findling, Robert L., Kiki Chang, Adelaide S. Robb, et al.. (2015). Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. Journal of the American Academy of Child & Adolescent Psychiatry. 54(12). 1020–1031.e3. 31 indexed citations
6.
Ostenfeld, Thor, Alok Krishen, Robert Lai, et al.. (2014). A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy. Clinical Journal of Pain. 31(4). 283–293. 34 indexed citations
7.
Tomson, Torbjörn, Lawrence J. Hirsch, Daniel Friedman, et al.. (2012). Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials. Epilepsia. 54(1). 135–140. 44 indexed citations
8.
Derosier, Frederick J., Fred D. Sheftell, Stephen D. Silberstein, et al.. (2011). Sumatriptan‐Naproxen and Butalbital: A Double‐Blind, Placebo‐Controlled Crossover Study. Headache The Journal of Head and Face Pain. 52(4). 530–543. 20 indexed citations
9.
Foster, Vicki J., et al.. (2010). Meta-Analysis of Suicidality in Placebo-Controlled Clinical Trials of Adults Taking Bupropion. The Primary Care Companion to The Journal of Clinical Psychiatry. 12(5). 20 indexed citations
10.
Hewett, K., et al.. (2009). Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. Journal of Psychopharmacology. 24(4). 521–529. 40 indexed citations
11.
Thase, Michael E., et al.. (2008). A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Sustained-Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. Journal of Clinical Psychopharmacology. 28(3). 302–307. 34 indexed citations
12.
Papakostas, George I., et al.. (2008). Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression). The Journal of Clinical Psychiatry. 69(8). 1287–1292. 87 indexed citations
13.
Hewett, K., W. Chrzanowski, Mark F. Schmitz, et al.. (2008). Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of Psychopharmacology. 23(5). 531–538. 47 indexed citations
14.
15.
Papakostas, George I., Susan G. Kornstein, Anita H. Clayton, et al.. (2007). Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender–age interactions. International Clinical Psychopharmacology. 22(4). 226–229. 20 indexed citations
16.
Jefferson, James W., A. John Rush, J. Craig Nelson, et al.. (2006). Extended-Release Bupropion for Patients With Major Depressive Disorder Presenting With Symptoms of Reduced Energy, Pleasure, and Interest. The Journal of Clinical Psychiatry. 67(6). 865–873. 42 indexed citations
17.
Clayton, Anita H., Harry A. Croft, Joseph P. Horrigan, et al.. (2006). Bupropion Extended Release Compared With Escitalopram. The Journal of Clinical Psychiatry. 67(5). 736–746. 99 indexed citations
18.
Papakostas, George I., et al.. (2006). Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors. Biological Psychiatry. 60(12). 1350–1355. 121 indexed citations
19.
Modell, Jack G., Norman E. Rosenthal, Alok Krishen, et al.. (2005). Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment with Bupropion XL. Biological Psychiatry. 58(8). 658–667. 80 indexed citations
20.
Westfall, Peter H., Alok Krishen, & S. Stanley Young. (1998). Using prior information to allocate significance levels for multiple endpoints. Statistics in Medicine. 17(18). 2107–2119. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel E. Falk Breakdown of academic impact, for papers by Thomas McRae Breakdown of academic impact, for papers by Harris A. Eyre Breakdown of academic impact, for papers by Margaret Rukstalis Breakdown of academic impact, for papers by Nassima Ait‐Daoud Breakdown of academic impact, for papers by Kaifeng Lu Breakdown of academic impact, for papers by Udi E. Ghitza Breakdown of academic impact, for papers by Loukia M. Spineli Breakdown of academic impact, for papers by Ajeet Singh Breakdown of academic impact, for papers by Eftihia Linardatos
Rankless by CCL
2026